













1 10.20 0.98 Yes MGN PDN,Tacro,
MMF
CR
2 1.67 1.17 No MGN PDN,Tacro CR
3 5.02 1.26 Yes MCD PDN,Tacro CR
4 2.04 2.96 Yes Tubulitis PDN CR
5 8.48 0.89 Yes MGN PDN,Tacro,
Siro
NR
6 1.57 2.6 Yes MGN PDN,MMF NR
7 0.61 0.8 Yes FSGS PDN,CsA CR
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285 S265Treatment: All patients were initially started on Predni-
sone (>0.5mg/kg) but only one had complete remission
with single agent prednisone. Other immunosuppressant
including Rituximab, Tacrolimus, Sirolimus, Cyclosporine,
MMF and Rituxan were used for non-responders to predni-
sone. Time and response to resolution to proteinuria was
variable as shown in the table below. No patients progressed
to ESRD and two patients had died as of the last follow up.
Conclusions: Our data conﬁrm the association of NRP with
chronic GVHD. Monitoring for proteinuria and timely
recognition of this entity may avoid the need for sustained
immunosuppression and nephronal loss.412
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Introduction: In the last two decades, there have been
multiple reasons for the improved outcomes of patients
undergoing allogeneic HSCT including more precise HLA
matching, the advent of reduced intensity conditioning
regimens, use of novel antimicrobial agents, increased op-
tions for immunosuppression and better patient selection.
However, the collective impact of these advances on out-
comes of patients who develop grade III or IV acute GVHD
remains unclear.
Methods: We performed a retrospective analysis of 428
patients with grade III or IV acute GVHD treated at Massa-
chusetts General Hospital and Dana-Farber Cancer Institute
from 1997-2012. We compared overall survival (OS), pro-
gression-free survival (PFS) from underlying disease, and
GVHD-related mortality (GRM) in 3 cohorts based on the
year of transplantation: 1997-2001 (n¼111), 2002-2006
(n¼112), and 2007-2012 (n¼205) using multivariate analysis
adjusting for age, diagnosis, disease status at transplant,
grade of acute GVHD, performance status, comorbidities,
conditioning intensity, HLA match, donor source, and donor-
patient gender match.Results: The most recent cohort of patients with grade III or
IV acute GVHD (2007-2012) was signiﬁcantly older (31%> 60
in 2007-2012, 12% > 60 in 2002-2006, and 4% > 60 in 1997-
2001, p < 0.001), and had lower proportion (35%) of grade IV
acute GVHD compared to earlier cohorts (52% in 1997-2001,
and 38% in 2002-2006, p¼ 0.01). The use of reduced intensity
conditioning, unrelated donors, and peripheral blood stem
cells among patients with grade III-IV acute GVHD increased
over time. In the unadjusted analysis, 12-month OS increased
over time (28% in 1997-2001, 35% in 2002-2006, 48% in
2007-2012, P ¼ 0.004) reﬂecting a decrease in 12-month
GRM (54% in 1997-2001, 51% in 2002-2006, 31% in 2007-
2012, P¼ 0.0001) and improvement in 12-month PFS (27% in
1997-2001, 30% in 2002-2006, 42% in 2007-2012, p ¼ 0.02).
After multivariate analysis, the period of transplantation
remained a strong predictor for OS, and the hazard ratio
(HRs) in 1997-2001 and 2002-2006 compared with 2007-
2012 were 1.55 (95% CI, 1.0-2.3, p ¼ 0.03), and 1.54 (95% CI,
1.2-2.1, p¼ 0.004), respectively. Similarly, more recent period
of transplantation remained a signiﬁcant predictor for lower
GRM [HRs in 1997-2001 and 2002-2006 compared with
2007-2012 were 1.65 (95% CI, 1.0-2.6, p¼0.04), and 2.28 (95%
CI 1.6-3.3, p < 0.001)] and longer PFS [HRs in 1997-2001 and
2002-2006 compared with 2007-2012 were 1.5 (95% CI, 1.0-
2.2, p ¼ 0.04), and 1.49 (95% CI 1.1-2.0, p ¼ 0.007)].
Conclusion: The outcomes of patients who develop grade III
or IV acute GVHD after allogeneic HSCT has improved over
time with lower GRM and improvement in PFS and OS. Our
results suggest that the multiple innovations in trans-
plantation care have led to improved outcomes in patients
with grade III and IV acute GVHD, and outcomes are not as
poor as historically reported.413
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The 2005 NIH chronic GVHD organ and overall clinical
severity score is based on the assessment of current status
regardless of whether abnormalities are caused by chronic
GVHD or other conditions. The score assignment does not
require knowledge of past manifestations, attribution, or
whether GVHD is still active; it simply describes the patient’s
current condition. The aim of this prospective study was to
analyze confounding factors affecting organ-speciﬁc 0-3
scores and global severity scores in patients with chronic
GVHD.
Patients and Methods: All 139 patients with NIH chronic
GVHD evaluated at our center between January and
September 2013 were included in this study. Medical pro-
viders completed the NIH 0-3 organ-speciﬁc scoring form
with two additional questions for each organ to identify
abnormalities that were 1) not attributed to chronic GVHD
(yes/no), or 2) attributed to chronic GVHD plus other causes
(yes/no). Causes of abnormalities attributed to causes other
than GVHD were described by the medical evaluator.
Results: Sixty-nine (50%) of the 139 patients had abnor-
malities attributed only to chronic GVHD. Fifty-nine (42%)
patients had abnormalities not attributed to chronic GVHD in
at least 1 organ, and 24 (17%) had abnormalities attributed to
chronic GVHD plus other causes in at least 1 organ. The
distribution of organ involvement according to attribution of
